In 2011, the pattern of China's pharmaceutical export location was stable, and the growth momentum achieved qualitative improvement. Jiangsu, Zhejiang, Guangdong, Shanghai, Shandong and other regions topped the list of pharmaceutical exports. The import scale of China's pharmaceutical commodities from major regions such as the United States, Europe, and Japan has further expanded.

According to statistics from the China Chamber of Commerce for Import and Export of Medicines and Health Products, from January to November 2011, there was no significant change in the existing pattern of China's pharmaceutical foreign trade industry. The increase in foreign trade was headed by Guizhou Province, which was 175.87%. The gains of other provinces and cities were within the range of 20% to 70%. Looking at the import and export trade of all provinces and cities across the country, except for the year-on-year decrease in the trade volume in Shanxi, Qinghai, and Tibet, the remaining provinces and cities all achieved double-digit growth.

In terms of exports, Jiangsu, Zhejiang, Guangdong, Shanghai and Shandong topped the list. From January to November 2011, exports totaled 27.071 billion U.S. dollars, accounting for 67.2% of total exports. Among them, Guangdong Province achieved a 36% increase in exports, but the export price fell by 5.19%. Exports of Hebei, Jilin, and Yunnan showed double-digit growth, but the number of exports declined by more than 10% year-on-year. The growth momentum was due to the increase in value-added products and the optimization of trade structure.

The growth rate of exports to emerging markets has increased and imports from major trading partners in Europe and the United States have increased. From January to November 2011, the three pillars of the major foreign trade markets of the medical industry continued to be maintained. Asia, Europe and North America together accounted for 86.07% of the total export share. Among them, Asia is still my largest export destination, with exports worth 15.961 billion U.S. dollars; Europe followed closely with exports of 11.199 billion U.S. dollars; North America was slightly inferior with US$ 7,514 million. Compared with the same period of 2010, the import and export growth in Europe, Asia, and North America was 39.63%, 34.80%, and 36.57%, respectively. My pharmaceutical products continue to squeeze into the nearly saturated traditional market.

From the point of view of the export destination country or region, the United States, India, Japan, Germany and South Korea are the top five export destinations in China, accounting for 44.07% of my export share, of which US$7.077 billion was exported to the United States, accounting for 17.57% of my export trade. . My export growth to emerging markets was significant, with an increase in market size of US$3.5 billion, which was US$700 million higher than the traditional market. Among them, my exports to ASEAN, India, Brazil, Russia, and South Africa increased by 41.17%, 28.24%, 48.69%, 47.27%, and 31.39%, respectively, which was significantly higher than the growth rate of the traditional market. The diversified development trend of the export market is even more pronounced. The diversification pattern was further established.

From the perspective of the importing country or region, China’s imports from major economies such as the United States, Europe, and Japan have further expanded. From January to November 2011, China's top five imports were the United States, Germany, Japan, Switzerland, and France. The five countries together accounted for 55.69% of China's pharmaceutical imports. Among them, the United States continued to sit steadily in the first position of imports from a single country with a total import value of US$4.989 billion. The import growth rate reached 47.09%, which is higher than my export growth rate to the United States by 20 percentage points. In addition, I have seen a surge in imports from Taiwan Province. The import value has increased by 30.88% year-on-year. The signing of the cross-strait economic cooperation framework agreement has a significant effect on promoting trade.